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DObjective: Angiogenesis involves the interplay of endothelial progenitor cells, pericytes, growth factors, and
cellular matrix components. The use of mesenchymal stem cells, which are closely related to pericytes and pro-
duce diverse angiogenic growth factors and matrix molecules, seems to be a promising therapeutic modality. We
postulate that the use of a combination cell product (mesenchymal stem cells in conjunction with a source of
endothelial progenitor cells) is safe and efficient and may optimize the clinical results obtained with the use
of endothelial progenitor cells alone. This study assessed whether the intramuscular infusion of a combination
cell product represents a viable, effective, and lasting therapeutic modality to improve perfusion in severely is-
chemic limbs.
Methods: Patients with limb ischemia (n ¼ 26) received an intramuscular (gastrocnemius) infusion of the
combination cell product in the most ischemic leg and a placebo product in the (less ischemic) contralateral
leg. Clinical follow-up (months 0.5, 1, 2, and 4 postinfusion) included evaluation of pain-free walking time,
ankle-brachial index, perfusion scintigraphy, and quality of life survey.
Results: No adverse events occurred after infusion. Efficacy assessment indicated that after cell infusion there
was a significant improvement in walking time and ankle-brachial index. In addition, technetium-99m-
tetrofosmin scintigraphy demonstrated a significant increase of perfusion in the treated limbs compared with
the respective control legs.
Conclusions: This phase II clinical trial shows that the use of a combination cell therapy is safe and effective
in increasing blood flow in the ischemic legs of patients with limb ischemia. (J Thorac Cardiovasc Surg
2012;144:377-82)During the last fewyears, therapeutic angiogenesis usingdif-
ferent populations of stem cells has emerged as a viable ther-
apeutic modality of last resource for patients with critical
limb ischemia not eligible for other revascularization proce-
dures.1,2 The rationale for the use of this therapy is based on
the notion that in addition to adult neovascularization from
preexisting vasculature, postnatal vasculogenesis mediated
by bone marrow (BM)-resident or circulating endothelial
progenitor cells (EPCs) also occurs in adults.3,4 Several
reports have demonstrated that the infusion of a source of
EPCs5 into critically ischemic limbs facilitates blood vessel
repair and improves clinical outcomes.6-10
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The Journal of Thoracic and Cavascular smooth muscle cells, vascular maturation, and ul-
timately blood flow. This sequence is orchestrated by sev-
eral growth factors that play pivotal roles.4,11,12 The
absence of any of these steps produces blood vessels that
are immature, permeable, and leaky.13
Because mesenchymal stem cells (MSCs) are involved in
smooth muscle cell and pericyte formation, as well as in the
manufacturing of several growth factors and extracellular
matrix molecules implicated in blood vessel formation,14-18
we believe the use of a combination of MSC and EPCs may
be more effective than the use of a single cell type (EPCs)
for the development of a mature and stable blood vessel.
In a previous phase I study,19 we assessed the feasibility
and safety of a combination stem cell product including
EPCs and MSC to treat patients with severe limb ischemia.
After 10 2months of follow-up, efficacy assessment dem-
onstrated improvements in walking time, ankle-brachial in-
dex (ABI), and quality of life (QoL). Angiographic
evaluation and technetium-99m-tetrofosmin (99mTc-TF)
perfusion scintigraphy scores confirmed increased perfu-
sion in the affected limbs. The present phase II study was
performed to further evaluate our findings from phase I.MATERIALS AND METHODS
Study Design
This phase II clinical trial was a single-center, prospective, nonrandom-
ized, open-label, placebo-controlled, safety/efficacy study of infusion ofrdiovascular Surgery c Volume 144, Number 2 377
TABLE 1. Clinical characteristics of the study population
ID
Patient characteristics
(sex, age, comorbidities)
Rutherford
class
Treated
leg
Cell
dose
1 M, 65 y, CAD, DM, HC, HTN, NHU 6 R Low
2 M, 53 y, CAD, HC 4 R Low
3 M, 57 y, HC, NHU 6 L High
4 M, 59 y, HC, HTN, NHU 4 L High
5 M, 67 y, CAD, DM, HTN, HC 4 L High
6 M, 61 y, CAD, HTN 4 R High
7 M, 73 y, CAD, DM, NHU, HTN 6 L High
8 F, 74 y, CAD, HTN, HC 4 L Low
9 F, 69 y, CAD, HTN 4 L Low
10 M, 51 y, CAD, HTN, HC 4 R Low
11 M, 55 y, CAD, DM, HTN 4 L Low
12 M, 70 y, CAD, DM 4 L Low
13 M, 63 y, DM, HC 4 L High
14 F, 72 y, HC 4 L High
15 F, 57 y, CAD, DM, HC, HTN 4 L High
16 M, 76 y, CAD, DM, HC, HTN 4 R High
17 M, 48 y, CAD, NHU 6 R High
18 M, 73 y, CAD, HC, HTN 4 L High
19 M, 56 y, CAD, DM, HC, HTN, NHU 4 R High
20 M, 67 y, CAD, DM, HC, HTN 4 R High
21 M, 48 y, CAD, HC, NHU 5 R High
22 M, 87 y, CAD, HC, HTN 4 R Low
23 M, 74 y, CAD, DM, HC 4 R Low
24 F, 59 y, CAD, DM, HC, HTN 4 R Low
25 M, 66 y, CAD, HC, NHU 6 L Low
26 F, 53 y, CAD 4 L Low
M, Male; CAD, coronary artery disease; DM, diabetes mellitus; HC, hypercholester-
olemia; HTN, hypertension; NHU, nonhealing ulcer; L, left; R, right; F, female.
Abbreviations and Acronyms
ABI ¼ ankle-brachial index
B ¼ brain
BM ¼ bone marrow
EPC ¼ endothelial progenitor cell
M ¼ muscle
MNC ¼ mononuclear cell
MSC ¼ mesenchymal stem cell
99mTc-TF ¼ technetium-99m-tetrofosmin
QoL ¼ quality of life
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Da combination stem cell product to the legs of patients with severe limb is-
chemia. This study was approved by the Western Institutional Review
Board (Olympia,Wash), and all subjects signed the informed consent form.
The end point of the study was to determine whether the infusion of the
cell product into the gastrocnemiusmuscle of ischemic limbs improves per-
fusion, as assessed by 99mTc-TF perfusion scintigraphy, ABI, pain-free
walking time, and QoL.
Patient Population
Twenty-six patients (Table 1) were enrolled from July 2008 to March
2010. The main inclusion criterion was the presence of severe limb ische-
mia, Rutherford class 4 to 6 in patients considered not candidates for per-
cutaneous or surgical revascularization. The main exclusion criteria were
previous angiogenic therapy, severe medical illness that could affect pa-
tients’ survival after enrollment, and a history of myocardial infarction
within the previous 3 months of screening.
Clinical Assessment
Themore symptomatic (Rutherford class 4–6) leg was chosen to receive
the infusion of cell product. These legs were subsequently randomly as-
signed to receive a low or high dose of the cell product, consisting of
900 3 106 BM mononuclear cells (MNCs) and 9 3 106 BM-MSC and
1800 3 106 BM-MNC and 18 3 106 BM-MSC, respectively. The less
symptomatic leg was used as control and received a placebo infusion.
The clinical condition of each leg was monitored by assessing the sever-
ity of ischemic pain, ABI, perfusion scintigraphy, and walking time. The
health-related QoL of patients was assessed by a QoL survey (Vascular
Quality of Life Questionnaire). In patients with ischemic ulcers, regular
measurements of the ulcer size were obtained during every office
follow-up.
Cell Preparation
All patients underwent a primary and secondary BM aspiration for prep-
aration of BM-MSC and BM-MNC (as a source of EPCs), respectively.
Cell processing was performed as previously published,19-21 followed by
immunophenotypical characterization of MSC and EPCs by flow
cytometry analysis (LSRII Analytic Flow Cytometer; Tulane National
Primate Research Center, Covington, La).
Preparation and Infusion of the Cell and Placebo
Products
The cell product for infusion was prepared by taking proper aliquots of
BM-MSC and BM-MNC into a final volume of 20.0 mL of infusion me-
dium (Dulbecco’s phosphate-buffered saline containing 5% human serum
albumin). The cell suspension was filtered through a cell strainer (BD Fal-
con, nylon, 100 mm; Bedford,Mass), and aliquots were taken for cell count,
viability, and microbiological control. As soon as the cell product was378 The Journal of Thoracic and Cardiovascular Surgapproved for infusion (lot-release criteria), portions (0.5 mL) of the cell
suspension were transferred to forty 1-mL syringes. For placebo product
infusion, forty 1-mL syringes were prepared, each containing 0.5 mL of in-
fusion media.
Release criteria for cell infusion was based on (1) no growth results for
USP Sterility (Fluid Thioglycollate Media and Soybean Casein Digest Me-
dium), (2) negative results for mycoplasma testing (polymerase chain reac-
tion), (3) negative result for a Gram stain test, and (4) a cell viability
(Trypan blue exclusion) 95% or greater. In addition, endotoxin content
in the cell product for infusion should be patient body weight of 5 EU/kg
or less.
After the cell product was approved by the lot-release criteria, cells were
infused in 4 areas of the gastrocnemius muscle of the treated leg. For this,
the muscle was divided into 4 quadrants and the cell product (in 40 syrin-
ges) was evenly infused. Under similar conditions, the placebo product was
infused into the control leg.
Clinical Assessment After Cell Infusion
Follow-upwas obtained at 2 weeks and 1, 2, and 4months after infusion.
During each visit, every patient underwent vital sign monitoring, chemistry
panel, complete blood count, resting ABI, pain-free walking time and dis-
tance on a treadmill (at 2.4 km/h, with no incline), and rest pain measure-
ment using a visual analog scale score.22
To assess leg perfusion, 99mTc-TF perfusion scintigraphy was per-
formed for each leg at baseline and months 1 and 4 after infusion. For
this, average counts per pixel in posterior projections of muscle regions
of equal size (M) and in brain (intracranial uptake, B) were drawn and
the muscle-to-brain uptake (M/B) ratio was calculated.7 The changes inery c August 2012
FIGURE 1. A, Changes in ABI for control and treated legs during follow-up. Left: ABI (mean standard deviation) for control legs; P values at months 1
and 4 were .05 in both cases. Right: ABI (mean  standard deviation) for treated legs; P values at months 1 and 4 were .05 and .01, respectively.
B, Pain-free walking time during follow-up. As noted, there is a gradual increment from the time of infusion to the last follow-up (month 4); P values
at months 5 and 4 were .03 and .001, respectively. ABI, Ankle-brachial index.
TABLE 2. Ankle-brachial index assessment at baseline, last, and
postlast study visits
ABI (mean ± SD)
Baseline
Last study visit
(month 4)
Postlast study visit*
(month 16.8 ± 5.9)
0.45  0.12 0.66  0.16 (P ¼ .023) 0.62  0.14 (P ¼ .062)
SD, Standard deviation. *Data for the 14 patients who returned for follow-up after the
last study visit of the protocol. The average time for postlast visits was 16.8  5.9
months after infusion of the combination cell product.
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analysis of the perfusion scintigraphy planar images taken on the legs of all
patients at baseline and months 1 and 4. Eleven patients returned for
follow-up (mean of 17 6 months) after the protocol had been concluded.
In these patients, ABI and QoL scores were recorded.
Data and Statistical Analysis
Statistical analysis was performed with NCSS statistical software
(Kaysville, Utah). All data are expressed as mean  standard deviation.
RESULTS
Processing Time and Characterization of the Cell
Product
The average time elapsed from BM aspiration to comple-
tion of MSC expansion and infusion procedures was 24.6
5.9 days. During this period, MSCs undergo the equivalent
of 2 1 passages after the primary culture (colony-forming
units fibroblasts). Although the time required to obtain the
final number of MSC targeted for infusion (low or high
dose) proved not to be significantly dependent on cell num-
ber, it was directly correlated with patient’s age, presence
and nature of comorbidities, and type of medication taken
(data not shown).
The combination cell product consisted of a population
of ex vivo expanded BM-MSCs characterized by a high ex-
pression of the mesenchymal antigens CD73, CD90, and
CD105 and a negative/dim expression of the myeloid sur-
face antigens CD45 and CD34,23 as well as a subset of
EPC-like cells (among the CD45þ population of BM-
MNC), coexpressing antigens CD144, CD133, and
CD34.24The Journal of Thoracic and CaProcedural Safety
There were no procedural complications related to BM
aspirations. The intramuscular cell infusion procedure was
well tolerated with no or only mild discomfort. The adopted
release criteria for cell infusion proved to be appropriate
and dependable, because infusion-related complications in
the first 24 hours did not develop in any patient. No adverse
events of the index or contralateral control limb were iden-
tified during the first 48 hours after infusion or the follow-up
period.Ankle-Brachial Index
In 5 of 26 patients, ABI assessment was not possible be-
cause of partial or total arterial wall calcification of the
treated leg. In all 21 patients with available ABI, the index
of the treated legs significantly increased compared with
baseline, as early as 1 month after cell infusion (P  .05).
This effect persisted (P  .001) during the entire follow-
up period. In contrast, there were no significant changes
of the ABIs in the contralateral (control) leg after placebordiovascular Surgery c Volume 144, Number 2 379
TABLE 3. 99mTc-TF perfusion scintigraphy analysis during
follow-up
M/B ratio* (average ± SD, n ¼ 23y)
Baseline Month 1 Month 4
1 1.20  1.54 (P  .05) 1.54  0.54 (P ¼ .03)
SD, Standard deviation. *For each patient, the M/B ratio at baseline was set to 1 and
used to calculate the relative M/B ratio at months 1 and 4. yIn 3 of 26 patients, M/B
values at baseline were unreliable and thus not used to calculate M/B ratios at months
1 and 4.
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Dinfusion (Figure 1, A). The favorable effect of cell infusion
in ABI was not correlated with cell dose because both low
and high cell dose products elicited an increment in ABI of
similar magnitude.
Fourteen patients returned for follow-up after the proto-
col had been concluded (after last visit study, 16.8  5.9
months). The ABI in these individuals (Table 2) was 0.62
 0.14, which is not different from the ABI recorded at
the last study visit (month 4 of follow-up).Walking Time
Pain-free walking time increased in all patients after cell
infusion. As seen in Figure 1, B, improvement in pain-free
walking time was observed in all patients, as early as 2
weeks after cell infusion (P  .03), and continued increas-
ing until the end of follow-up (P  .001). In each patient,
the increase in pain-free walking time correlated with
a change in pain severity and relief, as reported in the visual
analog scale.Quality of Life
QoL scores increased from 2.22  0.64 units to 3.24 
1.08 units (P .05) from baseline to month 4 after infusion,
respectively. The improvement in QoL was primarily due to
pain relief and improvement of physical functioning. All
patients reported satisfaction with the results of cell treat-
ment and recognized that the relief of pain in 1 leg (treated)
allows them to enhance their activity level, includingFIGURE 2. Visual analysis of calf perfusion using 99mTc-TF scintigraphy. Pos
and 23 (right).
380 The Journal of Thoracic and Cardiovascular Surgwalking and a significant reduction in the use of analgesics.
In 16 patients who returned for a postlast study visit, the
QoL score revealed stabilization or improvement of symp-
toms compared with the last 4-month follow-up.
99mTc-TF Perfusion Scintigraphy
The average (M/B) ratio calculated for legs infused with
the cell product showed a modest but not significant in-
crease from baseline to 1 month after infusion. However,
a significant increase in M/B ratio was observed 4 months
after cell infusion (P  .05) (Table 3). In the contralateral
control legs, the M/B ratios at baseline and at month 4 after
infusion were similar (data not shown).
In Figure 2, planar images of the posterior projection (re-
gion from knee to ankle) for the treated legs of 2 patients are
shown. The increase in radioactive tracer (from baseline to
month 4) sustains the assumption that the cell product en-
hances limb perfusion, as suggested by data in Table 3.
Chronic Ischemic Ulcers
We observed significant improvement or complete heal-
ing of chronic ischemic ulcers in 6 patients with this condi-
tion, which had not improved or healed before cell infusion
using conventional wound therapy (Figure 3).
DISCUSSION
In the present phase II clinical investigation, we confirm
our previous findings that the use of a BM-derived combina-
tion stem cell product is safe.19 None of the 26 patients par-
ticipating in this clinical trial developed procedural
complications after BM aspiration or after cell infusion
into the gastrocnemius muscle. Furthermore, at 4 months
of follow-up, none of the patients reported side effects re-
lated to cell infusions.
In addition, our results strongly suggest that the use of
a stem/progenitor cell product increases a limb’s blood
flow and improves claudication symptoms of limb ische-
mia. This was demonstrated by a significant increase in
ABI, perfusion scintigraphy, and pain-free walking distanceteroanterior views at baseline and month 4 after infusion for patients 5 (left)
ery c August 2012
FIGURE 3. Healing of ischemic ulcers. Compared with baseline, a significant healing and improvement of an ischemic ulcer in the third toe and complete
healing in the second toe (patient 1) are seen 4 at months after cell infusion. Representative data.
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improvement or complete healing in all 6 patients with
chronic ischemic ulcers. All patients reported symptoms
of improvement in the questionnaire of QoL and a decrease
in analgesics consumption. In contrast, in the contralateral
placebo control leg, there were no changes in ABI or perfu-
sion scintigraphy.
It is important to mention that all patients recognized and
were aware of major clinical improvements in the treated
(more ischemic) leg, despite no significant clinical changes
in the control (less ischemic) leg.
The cell doses used in this study were 30% and 60%
lower than that used in our phase I study19; however, in
all cases, the ratio of stem/progenitor (MSC to EPCs) cells
was 1. Accordingly, it seems that the beneficial effect in
clinical outcomes is more related to the presence of a reper-
toire of stem/progenitor repair cells rather than the absolute
number of infused cells. Previous studies have yielded ben-
eficial clinical outcomes by the infusion of different doses
of a single cell product (EPCs from diverse sources) to pa-
tients with limb ischemia after a relatively short (2-month)
follow-up.2,6,7 This makes it difficult to make meaningful
comparisons with the current study.
We assume that the addition of MSCs to the cell product
may play an important role in modulating and enhancing the
reported effect of MNCs in promoting neovascularization in
ischemic tissue.2 In addition to EPCs, formation of newma-
ture blood vessel requires the coordinated participation of
mural cells (vascular smooth cells and pericytes) and the
availability of local/distant growth factors, chemokines,
and extracellular matrix molecules.12-16 Thus, the infusion
of a combination cell product containing a source of
EPCs and MSCs may be critical to enhance angiogenesis
and to promote ischemic tissue repair. Whether the
clinical improvement is due to angiogenesis or an
increase in collateral remodeling25 by MSC remains specu-
lative at this stage.The Journal of Thoracic and CaCONCLUSIONS
The present results clearly suggest that this therapy is ef-
fective for the treatment of severe limb ischemia. Further in-
vestigation will be needed to determine the mechanism of
action involved in the clinical effect elicited by the combi-
nation stem cell therapy. The present study also shows that
this therapy is not only effective but also has persistent ben-
efits beyond the 4-month follow-up. In the group of patients
who were contacted after the end of the study (16.8  5.9
months after cell infusion), the ABI and QoL scores were
similar to those recorded at the last follow-up visit (4
months). Thus, the combination cell therapy used seems
to be effective in triggering a long-term and sustained clin-
ical effect. To our knowledge, this is the first study in the
United States that proves the feasibility, safety, and efficacy
of using a stem cell combination therapy in patients with
limb ischemia. In addition, evidence indicates that the ben-
eficial effect persists with time.
The authors thank all the study investigators, coordinators, and
patients who participated in this phase II clinical trial.
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